Literature DB >> 15501248

The permeability-reducing effects of prostacyclin and inhibition of Rho kinase do not counteract endotoxin-induced increase in permeability in cat skeletal muscle.

Cornelia Lundblad1, Peter Bentzer, P O Grände.   

Abstract

cAMP stimulation and Rho kinase inhibition are shown to decrease microvascular permeability during noninflammatory conditions, most likely by decreasing contractility of actomyosin filaments in the endothelial cell, but their effects on permeability during inflammatory conditions are not clarified. The objective of this in vivo study, performed on the autoperfused and denervated calf muscle of the cat, was therefore to evaluate to what extent cAMP stimulation and inhibition of Rho kinase reduce permeability at endotoxemia. Change in osmotic reflection coefficient for albumin was used as a measure of altered protein permeability and change in capillary filtration coefficient (CFC) as a measure of altered fluid permeability. After inducing a significant increase in protein and fluid permeability by infusion of lipopolysaccharide (LPS), we determined to what extent the increased permeability was decreased by the cAMP stimulator prostacyclin [1.0 ng/kg/min intravenously (iv)] or the Rho kinase inhibitor Y-27632 [1.05 microg/ml plasma/h intraarterially (ia)]. These doses are known to decrease permeability under noninflammatory conditions. The reflection coefficient for albumin and CFC were determined before and during LPS, and during LPS plus prostacyclin (n = 6) or LPS plus Y-27632 (n = 6). The reflection coefficient was reduced by about 30% (P < 0.05) and CFC was increased by about 25% (P < 0.05) by LPS, and these permeability parameters were not affected by prostacyclin or Y-27632. We conclude that cAMP stimulation and Rho kinase inhibition reduce permeability by other pathways and mechanisms than those by which permeability is increased during endotoxemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501248     DOI: 10.1016/j.mvr.2004.07.002

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  7 in total

Review 1.  Extracellular matrix, inflammation, and the angiogenic response.

Authors:  Alicia G Arroyo; M Luisa Iruela-Arispe
Journal:  Cardiovasc Res       Date:  2010-02-12       Impact factor: 10.787

2.  Pathophysiology of tissue fluid accumulation in inflammation.

Authors:  Helge Wiig
Journal:  J Physiol       Date:  2011-04-11       Impact factor: 5.182

3.  Involvement of Rho kinase (ROCK) in sepsis-induced acute lung injury.

Authors:  Ismail Cinel; Mustafa Ark; Phillip Dellinger; Tuba Karabacak; Lulufer Tamer; Leyla Cinel; Paul Michael; Shaimaa Hussein; Joseph E Parrillo; Anand Kumar; Aseem Kumar
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

4.  The suppression of myosin light chain (MLC) phosphorylation during the response to lipopolysaccharide (LPS): beneficial or detrimental to endothelial barrier?

Authors:  Natalia V Bogatcheva; Marina A Zemskova; Christophe Poirier; Tamara Mirzapoiazova; Irina Kolosova; Anne R Bresnick; Alexander D Verin
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

5.  Molecular mechanisms mediating protective effect of cAMP on lipopolysaccharide (LPS)-induced human lung microvascular endothelial cells (HLMVEC) hyperpermeability.

Authors:  Natalia V Bogatcheva; Marina A Zemskova; Yevgeniy Kovalenkov; Christophe Poirier; Alexander D Verin
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

6.  Protein kinase C-α signals P115RhoGEF phosphorylation and RhoA activation in TNF-α-induced mouse brain microvascular endothelial cell barrier dysfunction.

Authors:  Jing Peng; Fang He; Ciliu Zhang; Xiaolu Deng; Fei Yin
Journal:  J Neuroinflammation       Date:  2011-04-08       Impact factor: 8.322

7.  Transcapillary fluid flux and inflammatory response during neonatal therapeutic hypothermia: an open, longitudinal, observational study.

Authors:  Hans Jørgen Timm Guthe; Torbjørn Nedrebø; Jan Kristian Damås; Helge Wiig; Ansgar Berg
Journal:  BMC Pediatr       Date:  2018-02-23       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.